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The ability for governments across the globe to protect infants from diseases caused by viruses such as polio, 
human papillomavirus and rotavirus through immunization is highly contingent on the development and 
manufacture of efficacious and cost-effective vaccines. Historically, vaccine manufacturers operate at large, and 
at times, overstretched capacities to benefit from economies of scale. However, this has led to expensive batch 
failures that have added to cost and interrupted supply.  
 
This presentation describes a detailed economic analysis of multiple approaches for the manufacture of a Pichia 
pastoris-based vaccine with the aim of proposing strategies to produce a ultra-low cost vaccine against rotavirus 
with a target COG per dose of ¢15 for the finished drug product. This analysis was carried out using an 
advanced integrated decisional tool developed in-house. The case study assesses the cost-effectiveness of 
multiple manufacturing flowsheets combining different upstream and downstream techniques (e.g. fed-batch v 
perfusion, chromatography v crystallisation) as well as different facility designs (e.g. in-house v outsourced 
reagent production, fully integrated process v segregated process steps), across different geographic locations 
(Europe v India) and number of manufacturing sites. The key cost drivers across these scenarios were identified 
through a detailed sensitivity analysis. This allowed for process performance targets for sustainable supply of 
ultra-low cost rotavirus vaccines to be identified using an optimization algorithm.  
 
The key output of this work is to break the economies of scale model and explore how advances in 
manufacturing can be integrated into decisional tools models to facilitate the guaranteed, uninterrupted supply 
for low cost vaccines for Global Health.  
 
